Clinical trials: Sexual Desire Disorder
Hypoactive Sexual Desire Disorder
Dehydroepiandrosterone (DHEA) Treatment in Women and Men Experiencing Hypoactive Sexual Desire Disorder
Hypoactive Sexual Desire Disorder (HSDD) is a common syndrome characterized by low sexual desire causing marked distress. The involvement of DHEA in sexual function is unknown, however, DHEA treatment increased desire in…
- Trial name
- NCT00916396
- Testing
- Dehydroepiandrosterone
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Fibromyalgia, Sexual Dysfunction
Fibromyalgia and Sexual Functıonal Dısorder and Sexual Therapy
investigators aim to re-evaluate the findings of Fibromyalgia in patients whose FSFI scores return to normal levels after sexual therapy, by identifying patients with sexual dysfunction according to the FSFI scale applied in…
- Trial name
- NCT05272345
- Testing
- sexual therapy
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
Menopause, Sexual Dysfunction
Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause
Hypoactive sexual desire disorder (HSDD) is described as the most common form of female sexual dysfunction, particularly affecting peri- and postmenopausal women and is associated with significant distress and reduced quality of…
- Conditions
- Menopause, Sexual Dysfunction, Libido Disorder, Testosterone Deficiency
- Trial name
- TESTA MIND (NCT07408440)
- Testing
- Transdermal testosterone gel
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Sexual Dysfunction, Physiological
Effects of Lepidium Meyenii Walp on Sexual Function in Postmenopausal Women
Objective: To study the effects of Lepidium Meyenii in sexual function of postmenopausal women. Method: It will be held a clinical, prospective, randomized, double-blind, placebo-controlled study with 144 postmenopausal women…
- Trial name
- maca (NCT02624648)
- Testing
- The Female Sexual Function Index (FSFI), The Female Intervention Efficacy Index (FIEI), The Beck Depression Inventory II
- Where
- Brazil
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Universidade do Vale do Sapucai
Hypoactive Sexual Desire Disorder
A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)
The purpose of this study is to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women with Hypoactive Sexual Desire Disorder(with or without Decreased Arousal).
- Trial name
- NCT04943068
- Testing
- Bremelanotide
- Where
- South Korea
- Volunteers
- 193 people
- Sponsor
- Kwang Dong Pharmaceutical co., ltd.
Hypoactive Sexual Desire Disorder
Testosterone Therapy in Naturally Menopausal Women With Low Sexual Desire Receiving Transdermal Estrogen
The purpose of this study is to examine whether the transdermal testosterone system (TTS) is effective and safe in the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women who are on transdermal estrogen.
- Trial name
- NCT00384046
- Testing
- Testosterone
- Where
- 31 sites in Australia, Botswana and 3 more
- Volunteers
- 272 people
- Sponsor
- Warner Chilcott
Low Libido
Hypoactive Sexual Desire Disorder in Males
The purpose of this study is to determine if the study drug will increase sexual desire in men with HSDD. Half of the participants will take ADDYI while the other half will receive a placebo (a look-alike pill with no medicine).
- Trial name
- HSDD (NCT04002661)
- Testing
- Flibanserin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mohit Khera
Sexual Dysfunctions, Psychological
Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder
Safety profile of flibanserin over 28 additional weeks Distribution of preferred dose regimens
- Trial name
- NCT00601367
- Testing
- flibanserin flexible dose
- Where
- 68 sites in Austria, Belgium and 10 more
- Volunteers
- 480 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Sexual Dysfunctions, Psychological
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.
- Trial name
- NCT00996372
- Testing
- flibanserin
- Where
- 75 sites in United States
- Volunteers
- 949 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Menopause, Metabolic Syndrome
Low Sexual Desire and Metabolic Syndrome
Objective: To evaluate the prevalence of hypoactive sexual desire disorder (HSDD) in postmenopausal women diagnosed with metabolic syndrome (MS) and to compare it to that of a control group without MS.
- Conditions
- Menopause, Metabolic Syndrome, Hypoactive Sexual Desire Disorder, Obesity
- Trial name
- NCT02430987
- Testing
- Female sexual function index questionnaire, Evaluation of presence of metabolic syndrome, Evaluation of the body mass index
- Where
- Brazil
- Volunteers
- 291 people, healthy volunteers welcome
- Sponsor
- Faculdade de Ciências Médicas da Santa Casa de São Paulo
Sexual Dysfunctions, Psychological
Flibanserin Versus Placebo in Premenopausal Women With HSDD
To establish efficacy of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in 6-month treatment, vs placebo for Hypoactive Sexual Desire Disorder in premenopausal European women.
- Trial name
- NCT00491829
- Testing
- 50 mg qhs, 100 mg
- Where
- 86 sites in Austria, Belgium and 11 more
- Volunteers
- 945 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Hypoactive Sexual Desire Disorder
1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the…
- Trial name
- HSDD (NCT02333071)
- Testing
- Bremelanotide
- Where
- 91 sites in United States, Canada
- Volunteers
- 723 people
- Sponsor
- Palatin Technologies, Inc
Hypoactive Sexual Desire Disorder
The Effect of Individualised Homeopathic Treatment on Low Sexual Desire in Perimenopause
Low sexual desire, or decreased libido, is one of the most prevalent sexual complaints in females. Menopause is defined as the physiologic cessation of menses brought on by a decrease in ovarian function and is established once…
- Trial name
- NCT02419209
- Testing
- Sucrose pillules medicated with the Individualised Homeopathic Remedy
- Where
- South Africa
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Johannesburg
Breast Carcinoma, Cervical Carcinoma
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
This phase II randomized trial studies how well bupropion hydrochloride works in improving sexual desire in women with breast or gynecological cancer.
- Conditions
- Breast Carcinoma, Cervical Carcinoma, Ovarian Carcinoma, Postmenopausal
- Trial name
- NCT03180294
- Testing
- Bupropion 150 mg XL
- Where
- 362 sites in United States
- Volunteers
- 230 people
- Sponsor
- NRG Oncology
Breast Cancer, Vulvovaginal Signs and Symptoms
WISH, Feasibility of a Factorial Design
The primary aim of this study is to evaluate the feasibility of testing a multi-component intervention for sexual function using a factorial design.
- Conditions
- Breast Cancer, Vulvovaginal Signs and Symptoms, Sexual Desire Disorder, Body Image
- Trial name
- NCT07023822
- Testing
- Hyaluronic acid (HLA) Vaginal Moisturizer, Polycarbophil Vaginal Moisturizer, Hypnotic Relaxation
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- The University of Tennessee, Knoxville
Desire; Sexual, Aversion, Paraphilia
Acute Intense Paraphilic Desire (DSM-V) Down-Regulation Via taVNS Neuro-Modulation [Transcutaneous Afferent Vagus Nerve] With Future Operative Implant Consideration
Transcutaneous Afferent Vagus Nerve Stimulation [taVNS] is used to modulate persistent \& intense desire control amongst a specific participant group. Testing Center Order of Deliver Number
- Trial name
- NCT05482412
- Testing
- transcutaneous (superficial) afferent electrical nerve stimulation specific for vagus nerve
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- American University Of Montserrat
Sexual Dysfunction
Efficacy of Tibolone Versus Transdermal E2/NETA on Sexual Function in Naturally Postmenopausal Women (P06089)
Tibolone has been registered for treatment of menopausal symptoms. It is, however, not known what the effects are of tibolone in postmenopausal women diagnosed with sexual dysfunction.
- Trial name
- NCT00413764
- Testing
- tibolone, estradiol-norethisterone
- Volunteers
- 358 people
- Sponsor
- Organon and Co
Hypoactive Sexual Desire Disorder
Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido
This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in surgically menopausal women who are taking estrogen therapy.
- Trial name
- NCT00331123
- Testing
- Testosterone Transdermal System
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 562 people
- Sponsor
- Warner Chilcott
Hypoactive Sexual Desire Disorder (HSDD), Low Libido
Acupuncture for Sexual Dysfunction
Female Sexual Dysfunction (FSD) affects up to 43% of women in the United States and Hypoactive Sexual Desire Disorder (HSDD) is the most common form. There is no standardized treatment for this condition.
- Conditions
- Hypoactive Sexual Desire Disorder (HSDD), Low Libido, Female Sexual Dysfunction (FSD)
- Trial name
- NCT02070029
- Testing
- Acupuncture
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- TriHealth Inc.
Female Sexual Dysfunction
Viveve Geneveve Treatment of the Vaginal Introitus to Evaluate Safety and Efficacy
This study is evaluating the safety and efficacy of the Geneveve Treatment for women experiencing diminished sexual function following vaginal childbirth.
- Trial name
- VIVEVE II (NCT03479229)
- Testing
- Geneveve Treatment
- Where
- 21 sites in United States, Canada
- Volunteers
- 250 people
- Sponsor
- Viveve Inc.